Your browser doesn't support javascript.
loading
An Exome Sequencing Study to Assess the Role of Rare Genetic Variation in Pulmonary Fibrosis.
Petrovski, Slavé; Todd, Jamie L; Durheim, Michael T; Wang, Quanli; Chien, Jason W; Kelly, Fran L; Frankel, Courtney; Mebane, Caroline M; Ren, Zhong; Bridgers, Joshua; Urban, Thomas J; Malone, Colin D; Finlen Copeland, Ashley; Brinkley, Christie; Allen, Andrew S; O'Riordan, Thomas; McHutchison, John G; Palmer, Scott M; Goldstein, David B.
Afiliação
  • Petrovski S; 1 Institute for Genomic Medicine, Columbia University Medical Center, New York, New York.
  • Todd JL; 2 Department of Medicine, Austin Health and Royal Melbourne Hospital, The University of Melbourne, Melbourne, Victoria, Australia.
  • Durheim MT; 3 Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
  • Wang Q; 4 Duke Clinical Research Institute, Durham, North Carolina.
  • Chien JW; 3 Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
  • Kelly FL; 4 Duke Clinical Research Institute, Durham, North Carolina.
  • Frankel C; 1 Institute for Genomic Medicine, Columbia University Medical Center, New York, New York.
  • Mebane CM; 5 Gilead Sciences, Foster City, California.
  • Ren Z; 3 Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
  • Bridgers J; 3 Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
  • Urban TJ; 1 Institute for Genomic Medicine, Columbia University Medical Center, New York, New York.
  • Malone CD; 1 Institute for Genomic Medicine, Columbia University Medical Center, New York, New York.
  • Finlen Copeland A; 1 Institute for Genomic Medicine, Columbia University Medical Center, New York, New York.
  • Brinkley C; 6 Division of Pharmacotherapy and Experimental Therapeutics, Center for Pharmacogenomics and Individualized Therapy, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina; and.
  • Allen AS; 1 Institute for Genomic Medicine, Columbia University Medical Center, New York, New York.
  • O'Riordan T; 3 Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
  • McHutchison JG; 3 Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
  • Palmer SM; 7 Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina.
  • Goldstein DB; 5 Gilead Sciences, Foster City, California.
Am J Respir Crit Care Med ; 196(1): 82-93, 2017 07 01.
Article em En | MEDLINE | ID: mdl-28099038
ABSTRACT
RATIONALE Idiopathic pulmonary fibrosis (IPF) is an increasingly recognized, often fatal lung disease of unknown etiology.

OBJECTIVES:

The aim of this study was to use whole-exome sequencing to improve understanding of the genetic architecture of pulmonary fibrosis.

METHODS:

We performed a case-control exome-wide collapsing analysis including 262 unrelated individuals with pulmonary fibrosis clinically classified as IPF according to American Thoracic Society/European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association guidelines (81.3%), usual interstitial pneumonia secondary to autoimmune conditions (11.5%), or fibrosing nonspecific interstitial pneumonia (7.2%). The majority (87%) of case subjects reported no family history of pulmonary fibrosis. MEASUREMENTS AND MAIN

RESULTS:

We searched 18,668 protein-coding genes for an excess of rare deleterious genetic variation using whole-exome sequence data from 262 case subjects with pulmonary fibrosis and 4,141 control subjects drawn from among a set of individuals of European ancestry. Comparing genetic variation across 18,668 protein-coding genes, we found a study-wide significant (P < 4.5 × 10-7) case enrichment of qualifying variants in TERT, RTEL1, and PARN. A model qualifying ultrarare, deleterious, nonsynonymous variants implicated TERT and RTEL1, and a model specifically qualifying loss-of-function variants implicated RTEL1 and PARN. A subanalysis of 186 case subjects with sporadic IPF confirmed TERT, RTEL1, and PARN as study-wide significant contributors to sporadic IPF. Collectively, 11.3% of case subjects with sporadic IPF carried a qualifying variant in one of these three genes compared with the 0.3% carrier rate observed among control subjects (odds ratio, 47.7; 95% confidence interval, 21.5-111.6; P = 5.5 × 10-22).

CONCLUSIONS:

We identified TERT, RTEL1, and PARN-three telomere-related genes previously implicated in familial pulmonary fibrosis-as significant contributors to sporadic IPF. These results support the idea that telomere dysfunction is involved in IPF pathogenesis.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Predisposição Genética para Doença / Fibrose Pulmonar Idiopática / Exoma Tipo de estudo: Guideline / Prognostic_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Am J Respir Crit Care Med Assunto da revista: TERAPIA INTENSIVA Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Predisposição Genética para Doença / Fibrose Pulmonar Idiopática / Exoma Tipo de estudo: Guideline / Prognostic_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Am J Respir Crit Care Med Assunto da revista: TERAPIA INTENSIVA Ano de publicação: 2017 Tipo de documento: Article